Skip to content
Menu

Truist Securities Reiterates Buy on BeOne Medicines, Raises Price Target to $448

Benzinga Newsdesk 1 week ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Truist Securities analyst Gregory Renza reiterates BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $420 to $448.

Truist Securities analyst Gregory Renza reiterates BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $420 to $448.

Read at benzinga.com